ABPI names Novo Nordisk’s Pinder Sahota as its new president

The Association of the British Pharmaceutical Industry (ABPI) has appointed Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK as its new president.

He also chairs the Confederation of British Industries' Health Council and has previously served as vice chair of the European Medicines Group.

Effective from April 29, Sahota will lead on overseeing the ABPI, the ABPI Board, and the ABPI’s Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). He takes over from Ben Osborn of Pfizer.

Commenting on his new role, Sahota said: “After decades of scientific investment, we are now seeing the next generation of cutting-edge treatments being made available to patients. I’m determined to use my term as President of the ABPI to make sure that new, innovative medicines reach the people who need them.

"The past two years have demonstrated just how important medicines and vaccines are to our way of life. Improving how we use new medicines can now support the NHS to recover from the pandemic by addressing the significant variations which currently exist in care across the country."

"There is a real opportunity for the UK to build on our scientific excellence and continue to help patients across the country. I look forward to working closely with the Government, NHS and colleagues across the sector to make this a reality.”

Welcoming Pinder to the role, Richard Torbett, chief executive of the ABPI, said: “I’ve hugely enjoyed working with Pinder during his time as Vice President of the ABPI, and give him a warm welcome to the Presidency from the whole ABPI.

"Pinder is a passionate advocate for the industry and brings a wealth of experience to the Presidency. I look forward to working with Pinder to deliver on the ABPI’s long term strategy to achieve our ambitions for the sector in the UK.”